Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Perone Thomas Michael Insider Profile
4 Followers
Perone Thomas Michael, GC, Secretary at Ovid Therapeutics, holds 28.13K shares in Ovid Therapeutics (Ticker: OVID).
Perone Thomas Michael has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Perone Thomas Michael's holdings
Insider Roles
GC, Secretary
Roles that Perone Thomas Michael holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Perone Thomas Michael
Perone Thomas Michael's Trading History
List of latest transactions for each holding click on a transaction to see Perone Thomas Michael's performance on stock
You May Also Like
Perone Thomas Michael insider profile FAQ
What is the percentage of profitable transactions made by Perone Thomas Michael?
The percentage of profitable transactions made by Perone Thomas Michael is ―.
What is the average return per transaction made by Perone Thomas Michael?
The average return per transaction made by Perone Thomas Michael is ―.
What stocks does Perone Thomas Michael hold?
Perone Thomas Michael holds: OVID stocks.
What was Perone Thomas Michael’s latest transaction?
Perone Thomas Michael latest transaction was an Uninformative Buy of ―.
What was Perone Thomas Michael's most profitable transaction?
Perone Thomas Michael’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Perone Thomas Michael's role in Ovid Therapeutics?
Perone Thomas Michael's role in Ovid Therapeutics is GC, Secretary.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.